---
title: "US FDA Breakthrough Device designation granted for DynamX BTK for use in CLTI treatment below the knee"
date: "2024-03-22T16:06:03.000Z"
publishedDate: "22 mars 2024"
summary: "Elixir Medical has announced Breakthrough Device designation by the US Food and Drug Administration (FDA) for its novel DynamX BTK System, an implant for use in the treatment of narrowed or blocked vessels below-the-knee (BTK) in patients with chronic limb-threatening ischaemia (CLTI). The DynamX bioadaptor platform is a metallic device designed to support vessels during [&#8230;] The post US FDA Breakthrough Device designation granted for DynamX BTK for use in CLTI treatment below the knee appeared first on Vascular News ."
importance: ""
sourceUrl: "https://vascularnews.com/us-fda-breakthrough-device-designation-granted-for-dynamx-btk-for-use-in-clti-treatment-below-the-knee/"
tags: ["France", "Actualité", "Vascular News — Latest"]
permalink: "/papers/2024-03-22-us-fda-breakthrough-device-designation-granted-for-dynamx-btk-for-use-in-clti-treatment-below-the-knee"
imageUrl: "https://vascularnews.com/wp-content/uploads/sites/7/2024/03/Elixir-Medicals-DynamX.Image-courtesy-of-Elixir-Medical.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://vascularnews.com/us-fda-breakthrough-device-designation-granted-for-dynamx-btk-for-use-in-clti-treatment-below-the-knee/"
---

![US FDA Breakthrough Device designation granted for DynamX BTK for use in CLTI treatment below the knee](https://vascularnews.com/wp-content/uploads/sites/7/2024/03/Elixir-Medicals-DynamX.Image-courtesy-of-Elixir-Medical.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://vascularnews.com/us-fda-breakthrough-device-designation-granted-for-dynamx-btk-for-use-in-clti-treatment-below-the-knee/*

## L’essentiel

Elixir Medical has announced Breakthrough Device designation by the US Food and Drug Administration (FDA) for its novel DynamX BTK System, an implant for use in the treatment of narrowed or blocked vessels below-the-knee (BTK) in patients with chronic limb-threatening ischaemia (CLTI). The DynamX bioadaptor platform is a metallic device designed to support vessels during [&#8230;] The post US FDA Breakthrough Device designation granted for DynamX BTK for use in CLTI treatment below the knee appeared first on Vascular News .

## Lien source

https://vascularnews.com/us-fda-breakthrough-device-designation-granted-for-dynamx-btk-for-use-in-clti-treatment-below-the-knee/
